Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer.
Yanhua TianQingqing LiZhenlin YangShu ZhangJiachen XuZhijie WangHua BaiJianchun DuanBo ZhengWen LiYueli CuiXin WangRui WanKailun FeiJia ZhongShugeng GaoJie HeCarl M GayJianjun ZhangJie WangFuchou TangPublished in: Signal transduction and targeted therapy (2022)
Small-cell lung cancer (SCLC) is the most aggressive and lethal subtype of lung cancer, for which, better understandings of its biology are urgently needed. Single-cell sequencing technologies provide an opportunity to profile individual cells within the tumor microenvironment (TME) and investigate their roles in tumorigenic processes. Here, we performed high-precision single-cell transcriptomic analysis of ~5000 individual cells from primary tumors (PTs) and matched normal adjacent tissues (NATs) from 11 SCLC patients, including one patient with both PT and relapsed tumor (RT). The comparison revealed an immunosuppressive landscape of human SCLC. Malignant cells in SCLC tumors exhibited diverse states mainly related to the cell cycle, immune, and hypoxic properties. Our data also revealed the intratumor heterogeneity (ITH) of key transcription factors (TFs) in SCLC and related gene expression patterns and functions. The non-neuroendocrine (non-NE) tumors were correlated with increased inflammatory gene signatures and immune cell infiltrates in SCLC, which contributed to better responses to immune checkpoint inhibitors. These findings indicate a significant heterogeneity of human SCLC, and intensive crosstalk between cancer cells and the TME at single-cell resolution, and thus, set the stage for a better understanding of the biology of SCLC as well as for developing new therapeutics for SCLC.
Keyphrases
- single cell
- rna seq
- small cell lung cancer
- cell cycle
- high throughput
- gene expression
- endothelial cells
- induced apoptosis
- end stage renal disease
- transcription factor
- cell cycle arrest
- chronic kidney disease
- cell proliferation
- dna methylation
- ejection fraction
- genome wide
- newly diagnosed
- diffuse large b cell lymphoma
- small molecule
- patient reported outcomes
- multiple myeloma
- prognostic factors
- electronic health record
- brain metastases
- pi k akt
- data analysis
- drug induced